Ivan Jarry: Transplanting the seamlessness of consumer health to clinical trials

Send us a text

We speak to CEO of ObvioHealth, Ivan Jarry, about how clinical trials conducted for consumer products are different from trials in pharma and biotech - and how working with these has enabled ObvioHealth to create a holistic solution for decentralised trials. 

When COVID came, ObvioHealth’s platform built for consumer products was what pharma and biotech needed to continue their ongoing trials in a decentralized environment. Starting in smaller settings and building out to more complex trials created a unique value proposition of a holistic end-to-end platform. 

Measurements at home with technology that is more accurate and less of a burden for the participant. Letting the patients enter data with a data stamp increases the accuracy of the data. But going even further, technology can measure the data on it’s own. Like measuring the crying episodes of infants by recording and analyzing sound, rather than burdening the parents with recording. Or taking a picture of stool and letting the algorithm rate it.

Augmenting clinicians with digital technology has the potential to relieve some of the strain on healthcare, and increase access to marginalised groups to clinical trials - and also help identify more narrow patient populations for certain drug modalities. 

Notes: 

Guest Ivan Jarry: https://www.linkedin.com/in/ivan-jarry-a1a09535/ 

ObvioHealth: https://www.obviohealth.com/ 

________
Reach out to Sam Parnell and Ivanna Rosendal

Join the conversation on our LinkedIn page